CN102659945B - 抗C5aR抗体及其应用 - Google Patents
抗C5aR抗体及其应用 Download PDFInfo
- Publication number
- CN102659945B CN102659945B CN201110205361.6A CN201110205361A CN102659945B CN 102659945 B CN102659945 B CN 102659945B CN 201110205361 A CN201110205361 A CN 201110205361A CN 102659945 B CN102659945 B CN 102659945B
- Authority
- CN
- China
- Prior art keywords
- antibody
- c5ar
- cell
- sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
Abstract
Description
Claims (25)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35096102P | 2002-01-25 | 2002-01-25 | |
US60/350,961 | 2002-01-25 | ||
CNA038069482A CN1642983A (zh) | 2002-01-25 | 2003-01-24 | 抗C5aR抗体及其应用 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA038069482A Division CN1642983A (zh) | 2002-01-25 | 2003-01-24 | 抗C5aR抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102659945A CN102659945A (zh) | 2012-09-12 |
CN102659945B true CN102659945B (zh) | 2016-12-21 |
Family
ID=27613447
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA038069482A Pending CN1642983A (zh) | 2002-01-25 | 2003-01-24 | 抗C5aR抗体及其应用 |
CN201110205361.6A Expired - Lifetime CN102659945B (zh) | 2002-01-25 | 2003-01-24 | 抗C5aR抗体及其应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA038069482A Pending CN1642983A (zh) | 2002-01-25 | 2003-01-24 | 抗C5aR抗体及其应用 |
Country Status (11)
Country | Link |
---|---|
US (3) | US8071096B2 (zh) |
EP (2) | EP2371861B1 (zh) |
JP (2) | JP4559081B2 (zh) |
CN (2) | CN1642983A (zh) |
AU (3) | AU2003202297C1 (zh) |
CA (1) | CA2476773C (zh) |
DK (1) | DK2371861T3 (zh) |
ES (2) | ES2561828T3 (zh) |
NZ (1) | NZ534399A (zh) |
WO (1) | WO2003062278A1 (zh) |
ZA (1) | ZA200406347B (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2371861B1 (en) | 2002-01-25 | 2017-08-09 | Novo Nordisk A/S | Monoclonal antibodies against extracellular loops of C5aR |
AU2003290605A1 (en) * | 2002-11-05 | 2004-06-03 | The Regents Of The University Of Michigan | Compositions and methods for the diagnosis and treatment of sepsis |
RU2009110154A (ru) * | 2006-08-22 | 2010-09-27 | Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) | АНТИТЕЛА ПРОТИВ C5aR С УЛУЧШЕННЫМИ СВОЙСТВАМИ |
GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
WO2008109742A1 (en) * | 2007-03-06 | 2008-09-12 | Novo Nordisk A/S | Modulation of complement system activation for treatment of bleeding-related inflammation |
AU2009215846B2 (en) * | 2008-02-19 | 2014-08-14 | The Trustees Of The University Of Pennsylvania | Complement inhibitors as therapeutic agents for treatment of cancer |
US8268972B2 (en) * | 2008-02-20 | 2012-09-18 | G2 Inflammation Pty Ltd | Humanized anti-C5aR antibodies |
AU2010264520A1 (en) | 2009-06-23 | 2012-01-19 | Alexion Pharmaceuticals, Inc. | Bispecific antibodies that bind to complement proteins |
WO2011100477A2 (en) * | 2010-02-10 | 2011-08-18 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
EP2468295A1 (en) | 2010-12-21 | 2012-06-27 | Affiris AG | Vaccines based on peptides of the complement protein C5a |
DK2718322T3 (en) * | 2011-06-06 | 2018-12-03 | Novo Nordisk As | THERAPEUTIC ANTIBODIES |
PL3462173T3 (pl) | 2012-08-21 | 2021-08-16 | Janssen Pharmaceutica Nv | Przeciwciała przeciwko rysperydonowi i ich zastosowanie |
WO2014180961A1 (en) * | 2013-05-08 | 2014-11-13 | Novo Nordisk A/S | Use of c5ar antagonists |
WO2015080657A1 (en) * | 2013-11-28 | 2015-06-04 | Ge Healthcare Bio-Sciences Ab | Stabilization of fermented beverages |
SG11201607740TA (en) * | 2014-03-20 | 2016-10-28 | Inflarx Gmbh | Inhibitors of c5a for the treatment of viral pneumonia |
CN106957366B (zh) * | 2016-01-12 | 2022-02-01 | 上海昀怡健康科技发展有限公司 | 一种C5aR抗体及其制备方法和应用 |
AU2020235263A1 (en) * | 2019-03-14 | 2021-09-02 | Morphosys Ag | Antibodies targeting C5aR |
TW202140553A (zh) | 2020-01-13 | 2021-11-01 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
US20230340140A1 (en) | 2020-08-12 | 2023-10-26 | Innate Pharma | Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab |
CA3173944A1 (en) | 2021-01-13 | 2022-07-21 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995000164A1 (en) * | 1993-06-18 | 1995-01-05 | The Scripps Research Institute | PEPTIDES AND ANTIBODIES TO HUMAN C5a RECEPTOR AND METHOD OF TREATMENT |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
US4172124A (en) | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
US4568649A (en) | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
JPH02262599A (ja) | 1989-01-03 | 1990-10-25 | Merck & Co Inc | ヒト多形核白血球からの精製C5aレセプター |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5284746A (en) | 1990-02-08 | 1994-02-08 | Zymogenetics, Inc. | Methods of producing hybrid G protein-coupled receptors |
US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
SG41929A1 (en) | 1992-09-25 | 1997-08-15 | Commw Scient Ind Res Org | Target binding polypeptide |
DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5861272A (en) * | 1995-06-02 | 1999-01-19 | Human Genome Sciences, Inc. | C5A receptor |
JPH08109200A (ja) | 1994-08-19 | 1996-04-30 | Takeda Chem Ind Ltd | 抗C5aレセプター抗体、その製造法および用途 |
AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
JPH11507513A (ja) | 1995-06-05 | 1999-07-06 | インサイト・ファーマスーティカルズ・インコーポレイテッド | C5a様7膜貫通受容体 |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
CA2279344A1 (en) | 1997-01-31 | 1998-08-06 | Incyte Pharmaceuticals, Inc. | Human c5a-like receptor |
WO1998049198A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
WO2002038767A2 (en) | 2000-11-07 | 2002-05-16 | Genetics Institute, Llc. | G protein-coupled receptor protein and nucleic acid molecules and uses therefor |
EP1409646B1 (en) | 2000-12-19 | 2012-06-13 | Altor BioScience Corporation | Transgenic animals comprising a humanized immune system |
WO2002061087A2 (en) | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
TWI334439B (en) | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
ATE453661T1 (de) | 2001-09-27 | 2010-01-15 | Merck & Co Inc | Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodieren, damit verwandte, nichthumane transgene tiere und assayverfahren |
US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
EP2371861B1 (en) | 2002-01-25 | 2017-08-09 | Novo Nordisk A/S | Monoclonal antibodies against extracellular loops of C5aR |
CA2498264A1 (en) | 2002-09-09 | 2004-05-13 | Nura, Inc. | G protein coupled receptors and uses thereof |
CA2508375C (en) | 2002-12-02 | 2014-05-27 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
WO2005040219A1 (en) | 2003-10-28 | 2005-05-06 | Novo Nordisk A/S | Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
US8071839B2 (en) | 2003-12-24 | 2011-12-06 | G2 Inflammation Pty Ltd | Transgenic mouse comprising a polynucleotide encoding human or humanized C5aR and methods of production and use |
US7829673B2 (en) | 2005-03-23 | 2010-11-09 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
US8084024B2 (en) | 2006-08-22 | 2011-12-27 | G2 Inflammation Pty Ltd | Method for producing antibodies |
RU2009110154A (ru) | 2006-08-22 | 2010-09-27 | Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) | АНТИТЕЛА ПРОТИВ C5aR С УЛУЧШЕННЫМИ СВОЙСТВАМИ |
WO2008030564A2 (en) | 2006-09-08 | 2008-03-13 | Verenium Corporation | Aglycosylated antibodies and methods of making and using those antibodies |
WO2009053368A1 (en) | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Single ifn-beta fused to a mutated igg fc fragment |
US8268972B2 (en) | 2008-02-20 | 2012-09-18 | G2 Inflammation Pty Ltd | Humanized anti-C5aR antibodies |
WO2010000864A1 (en) | 2008-07-04 | 2010-01-07 | Novo Nordisk A/S | Method for producing monoclonal antibodies |
KR20120130757A (ko) | 2010-02-26 | 2012-12-03 | 노보 노르디스크 에이/에스 | 안정한 항체 함유 조성물 |
CA2800188A1 (en) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
-
2003
- 2003-01-24 EP EP10009060.4A patent/EP2371861B1/en not_active Expired - Lifetime
- 2003-01-24 ES ES03700693.9T patent/ES2561828T3/es not_active Expired - Lifetime
- 2003-01-24 EP EP03700693.9A patent/EP1476469B1/en not_active Expired - Lifetime
- 2003-01-24 NZ NZ534399A patent/NZ534399A/en not_active IP Right Cessation
- 2003-01-24 DK DK10009060.4T patent/DK2371861T3/da active
- 2003-01-24 JP JP2003562155A patent/JP4559081B2/ja not_active Expired - Lifetime
- 2003-01-24 US US10/502,145 patent/US8071096B2/en active Active
- 2003-01-24 CN CNA038069482A patent/CN1642983A/zh active Pending
- 2003-01-24 CN CN201110205361.6A patent/CN102659945B/zh not_active Expired - Lifetime
- 2003-01-24 AU AU2003202297A patent/AU2003202297C1/en not_active Ceased
- 2003-01-24 WO PCT/AU2003/000084 patent/WO2003062278A1/en active IP Right Grant
- 2003-01-24 ES ES10009060.4T patent/ES2646792T3/es not_active Expired - Lifetime
- 2003-01-24 CA CA2476773A patent/CA2476773C/en not_active Expired - Fee Related
-
2004
- 2004-08-11 ZA ZA200406347A patent/ZA200406347B/en unknown
-
2006
- 2006-01-24 AU AU2006200320A patent/AU2006200320A1/en not_active Abandoned
-
2009
- 2009-11-19 AU AU2009238340A patent/AU2009238340A1/en not_active Withdrawn
- 2009-11-30 JP JP2009271989A patent/JP5202501B2/ja not_active Expired - Lifetime
-
2011
- 2011-10-24 US US13/280,250 patent/US8221757B2/en not_active Expired - Lifetime
-
2012
- 2012-06-15 US US13/525,092 patent/US8673305B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995000164A1 (en) * | 1993-06-18 | 1995-01-05 | The Scripps Research Institute | PEPTIDES AND ANTIBODIES TO HUMAN C5a RECEPTOR AND METHOD OF TREATMENT |
Non-Patent Citations (2)
Title |
---|
Analysis of C5a receptor by monoclonal antibody;WATANABE H. et al.;《JOURNAL OF IMMUNOLOGICAL METHODS》;19950911;第185卷(第1期);全文 * |
Probing the human receptor for C5a anaphylatoxin with site-directed antibodies.identification of a potential ligand binding site on the NH2-terminal domain;OPPERMANN M. et al.;《JOURNAL OF IMMUNOLOGY》;19931001;第151卷(第7期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
EP1476469B1 (en) | 2015-11-18 |
AU2003202297B2 (en) | 2005-11-17 |
US20120121584A1 (en) | 2012-05-17 |
CA2476773A1 (en) | 2003-07-31 |
WO2003062278A1 (en) | 2003-07-31 |
EP1476469A1 (en) | 2004-11-17 |
DK2371861T3 (da) | 2017-11-20 |
AU2006200320A1 (en) | 2006-02-16 |
US8071096B2 (en) | 2011-12-06 |
US8221757B2 (en) | 2012-07-17 |
EP1476469A4 (en) | 2005-11-23 |
ES2561828T3 (es) | 2016-03-01 |
JP2005535562A (ja) | 2005-11-24 |
CA2476773C (en) | 2013-05-28 |
NZ534399A (en) | 2008-08-29 |
CN1642983A (zh) | 2005-07-20 |
CN102659945A (zh) | 2012-09-12 |
JP5202501B2 (ja) | 2013-06-05 |
AU2003202297C1 (en) | 2006-05-18 |
US20130129717A1 (en) | 2013-05-23 |
EP2371861B1 (en) | 2017-08-09 |
EP2371861A1 (en) | 2011-10-05 |
ZA200406347B (en) | 2006-06-28 |
JP4559081B2 (ja) | 2010-10-06 |
AU2009238340A1 (en) | 2009-12-10 |
US8673305B2 (en) | 2014-03-18 |
ES2646792T3 (es) | 2017-12-18 |
JP2010051323A (ja) | 2010-03-11 |
US20050244406A1 (en) | 2005-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102659945B (zh) | 抗C5aR抗体及其应用 | |
CN104592388B (zh) | 一种抗人Tim‑3的单克隆抗体的抗原结合部分 | |
CN102988959B (zh) | Nkg2d的调节 | |
CN104059149B (zh) | 具有改进性能的抗‑C5aR抗体 | |
CN101970494A (zh) | 人源化抗-C5aR抗体 | |
AU2003202297A1 (en) | Anti-C5aR antibodies and uses thereof | |
CN109265547A (zh) | 一种抗cd47抗体及其应用 | |
CN104987420B (zh) | 抗cd20的全人源单克隆抗体及其应用 | |
CN110872353A (zh) | 特异性结合pcsk9抗原的纳米抗体及其制备方法和应用 | |
CN105061596A (zh) | 人b淋巴细胞刺激因子的单克隆抗体及其应用 | |
JPH1030000A (ja) | 腫瘍血管内皮表面の抗原を認識するモノクローナル抗体 | |
CN105001331A (zh) | 一种vegf单克隆抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: NOVO NORDISK A/S Free format text: FORMER OWNER: G2 THERAPIES PTY LTD. Effective date: 20150624 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: New South Wales, Australia Applicant after: G2 treatment Pte. Ltd. Address before: New South Wales, Australia Applicant before: G2 Therapies Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: Free format text: CORRECT: APPLICANT; FROM: G2 THERAPIES LTD. TO: G2 THERAPIES PTY LTD. |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150624 Address after: Denmark bagsvaerd Applicant after: NOVO NORDISK A/S Address before: New South Wales, Australia Applicant before: G2 treatment Pte. Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20161221 |